Swarm immunization with envelopes from CH505
In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH505) and selections therefrom, and methods for swarm immunizations using combinations of HIV-1 envelopes.
1. A recombinant HIV-1 envelope protein wherein the recombinant HIV-1envelope protein is a HIV-1 gp160 M5 envelope protein comprising amino acids 30 through 846 of SEQ ID NO:307, a HIV-1 gp140 M5 envelope protein derived from a HIV-1 gp160 M5 envelope protein comprising amino acids 30 through 846 of SEQ ID NO:307, a HIV-1 gp145 M5 envelope protein comprising amino acids 30 through 694 of SEQ ID NO:469, a HIV-1 gp120d8 M5 envelope protein comprising amino acids 29through 486 of SEQ ID NO:322, or a HIV-1 gp120 M5 envelope protein comprising amino acid sequence MWVTVYYG followed immediately by amino acids 30 through 486 of SEQ ID NO:322.
2. The recombinant HIV-1 envelope protein according to claim 1 , wherein the recombinant HIV-1 envelope protein is a HIV-1 gp120d8 M5 envelope protein comprising amino acids 29 through 486 of SEQ ID NO:322.
3. The recombinant HIV-1 envelope protein according to claim 1 , wherein the recombinant HIV-1 envelope protein is a HIV-1 gp120 M5 envelope protein comprising amino acid sequence MWVTVYYG followed immediately by amino acids 30 through 486 of SEQ ID NO:322.
4. The recombinant HIV-1 envelope protein according to claim 1 , wherein the recombinant HIV-1 envelope protein is a HIV-1 gp140 M5 envelope protein derived from a HIV-1 gp160 M5 envelope protein comprising amino acids 30 through 846 of SEQ ID NO:307.
5. The recombinant HIV-1 envelope protein according to claim 1 , wherein the recombinant HIV-1 envelope protein is a HIV-1 gp145 M5 envelope protein comprising amino acids 30 through 694 of SEQ ID NO:469.
6. The recombinant HIV-1 envelope protein according to claim 1 , wherein the recombinant HIV-1 envelope protein is a HIV-1 gp160 M5 envelope protein comprising amino acids 30 through 846 of SEQ ID NO:307.
7. A nucleic acid comprising a nucleotide sequence encoding any one of the HIV-1 envelope proteins according to claim 1 .
8. A vector comprising the nucleic acid according to claim 7 , wherein the nucleic acid is operably linked to a promoter.
9. A composition comprising any one of the recombinant HIV-1 envelope proteins according to claim 1 , and an adjuvant.
10. A composition comprising said nucleic acid according to claim 7 and an adjuvant.
11. A composition comprising said vector according to claim 8 and an adjuvant.
12. A method of inducing an immune response to HIV-1 comprising administering a composition comprising any one of the recombinant HIV-1 envelope proteins according claim 1 , to a subject in an amount sufficient to effect said induction.
13. The method of claim 12 , wherein the composition comprises an adjuvant.
14. A method of inducing an immune response to HIV-1 comprising administering a composition comprising said nucleic acid according to claim 7 to a subject in an amount sufficient to effect said induction.
15. The method of claim 14 , wherein the composition comprises an adjuvant.
16. A method of inducing an immune response to HIV-1 comprising administering a composition comprising
a. said vector according to claim 8 ; and
b. an adjuvant to a subject in an amount sufficient to effect said induction.
17. The method of claim 15 , wherein the composition is administered as a prime in a prime boost regimen.
18. The method of claim 17 , wherein a composition comprising at least one additional HIV-1 envelope protein from Table 14 or any combination thereof is administered as a boost in a prime boost regimen.
19. The method of claim 16 , wherein the composition is administered as a prime in a prime boost regimen.
20. The method of claim 19 , wherein a composition comprising at least one additional HIV-1 envelope protein from Table 14 or any combination thereof is administered as a boost in a prime boost regimen.